Myelodysplastic Syndromes
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | PDGFRA rearrangements | Myelodysplastic Syndromes | Imatinib | FDA |
| Sensitivity (+) | PDGFRB rearrangements | Myelodysplastic Syndromes | Imatinib | FDA |
| Sensitivity (+) | IDH1 p.R132C | Myelodysplastic Syndromes | Ivosidenib | FDA |
| Sensitivity (+) | IDH1 p.R132G | Myelodysplastic Syndromes | Ivosidenib | FDA |
| Sensitivity (+) | IDH1 p.R132H | Myelodysplastic Syndromes | Ivosidenib | FDA |
| Sensitivity (+) | IDH1 p.R132L | Myelodysplastic Syndromes | Ivosidenib | FDA |
| Sensitivity (+) | IDH1 p.R132S | Myelodysplastic Syndromes | Ivosidenib | FDA |
| Sensitivity (+) | 5q deletion | Myelodysplastic Syndromes | Lenalidomide | FDA |
| Sensitivity (+) | PDGFRA rearrangements | Myelodysplastic Syndromes | Imatinib | HC |
| Sensitivity (+) | PDGFRB rearrangements | Myelodysplastic Syndromes | Imatinib | HC |
| Sensitivity (+) | 5q deletion | Myelodysplastic Syndromes | Lenalidomide | HC |